Xtandi(Enzalutamide)
4503.T
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Astellas Pharma Inc.
$3.40B
Medicare cost, 2024
$3.40B
Medicare cost, 2024
Medicare drug plans spent $3.4 billion on Xtandi (enzalutamide) in 2024, for 255,605 prescriptions and refills filled by 35,359 patients. It ranks 14th among all drugs by Medicare drug plan spending. Spending rose 31% from 2023 to 2024. At about $13,301 per prescription it is a high-cost drug.
Medicare cost, 2024
$3.40B
+30.8% from 2023
Prescriptions
256K
$13,301.42 per claim
Patients
35K
12,459 prescribers
Total spending, 2024
$3.40B
$96,156.56 per patient
Questions and answers
How much does Medicare spend on Xtandi?
Medicare prescription drug plans paid $3.40B for Xtandi in 2024, for 255,605 prescriptions and refills to 35,359 patients (up 30.8% from 2023). The average cost per claim was $13,301.42.
Which state spends the most on Xtandi?
California had the highest Medicare cost for Xtandi in 2024: $353.8M for 27,174 claims, followed by Florida ($278.2M).
Who prescribes Xtandi the most?
Sukumar Ethirajan, hematology in Overland Park, KS, had the highest Medicare cost for Xtandi in 2024: 1,540 claims costing $21.5M.
Who makes Xtandi?
Xtandi is made by Astellas Pharma Inc. (4503.T), listed in the Medicare spending data as Astellas Pharma.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Xtandi was $3.40B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Xtandi, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Sukumar Ethirajan Overland Park, KS | Hematology | 1,540 | 229 | $21.5M |
| Ryan J Malone Jeffersonville, IN | Urology | 777 | 107 | $10.5M |
| Geoffrey J Bisignani Latrobe, PA | Urology | 669 | 71 | $8.9M |
| John M Rutkowski Sanborn, NY | Urology | 633 | 86 | $8.0M |
| Luke T Nordquist Omaha, NE | Medical Oncology | 540 | 82 | $7.3M |
| Stewart T Landau American Fork, UT | Urology | 486 | 72 | $6.7M |
| Zachary D Reardon Mobile, AL | Urology | 506 | 63 | $6.7M |
| Peter A Zeman Wilmington, NC | Urology | 482 | 57 | $6.5M |
| Aaron D Berger Chicago Ridge, IL | Urology | 481 | 76 | $6.4M |
| Timothy J Leroy Knoxville, TN | Urology | 427 | 58 | $6.0M |
| Benjamin H Lowentritt Baltimore, MD | Urology | 379 | 70 | $5.5M |
| Walter Rayford Memphis, TN | Urology | 392 | 72 | $5.4M |
| William B Townsend Charlotte, NC | Urology | 376 | 49 | $5.2M |
| Jim Hsiang Corpus Christi, TX | Radiation Oncology | 352 | 45 | $4.9M |
| Mark D Greenberger Memphis, TN | Urology | 358 | 48 | $4.9M |
| Daniel C Danila New York, NY | Medical Oncology | 348 | 57 | $4.8M |
| Brian R Evans Florence, SC | Urology | 344 | 45 | $4.7M |
| Mark J Saslawsky Memphis, TN | Urology | 340 | 34 | $4.6M |
| Mark G Delworth Jr. Blue Ash, OH | Urology | 342 | 36 | $4.5M |
| Susan M Sargent Rochester, NY | Nurse Practitioner | 364 | 50 | $4.5M |
| Joelle P Hamilton Homewood, AL | Medical Oncology | 338 | 57 | $4.4M |
| David S Morris Hendersonville, TN | Urology | 322 | 59 | $4.3M |
| Pratik S Desai Woodbridge, VA | Urology | 294 | 39 | $4.1M |
| Scott B Sellinger Tallahassee, FL | Urology | 284 | 31 | $3.9M |
| David Degrassi Huntley, IL | Nurse Practitioner | 323 | 57 | $3.6M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 10,877 | 189,079 | 27,801 | $2.44B |
| 2023 | 11,194 | 191,565 | 28,632 | $2.60B |
| 2024 | 12,459 | 255,605 | 35,359 | $3.40B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Astellas Pharma | 255,669 | $3.40B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 5
- RxNorm concept IDs
- 1307303, 1307309, 2390644, 2390646, 2390648
- Application numbers
- NDA203415, NDA213674
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 58,866 side-effect reports named enzalutamide, the active ingredient of Xtandi (reports from 2012 on). 36,319 of them (61.7%) were serious, 11,400 named a death and 11,199 named a hospital stay. The reactions named most often were fatigue, death and malignant neoplasm progression. 11,304 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
58,866
2,634 in 2025 (+5.0% from 2024)
Serious
61.7%
36,319 reports
Deaths named
11,400
19.4% of reports
Hospital stays
11,199
19.0% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Xtandi?
58,866 reports from 2012 through September 2026 named enzalutamide, the active ingredient of Xtandi. 36,319 of them (61.7%) were serious, 11,400 named a death and 11,199 named a hospital stay.
What are the most reported side effects of Xtandi?
10,332 reports named fatigue, the reaction named most often, followed by death (7,715) and malignant neoplasm progression (5,499). In the last 5 years the reaction named most often was fatigue (1,934 reports). A report can name several reactions.
How many side-effect reports named Xtandi in 2025?
2,634 reports were received in 2025 (+5.0% from 2024). 2026 so far: 1,225 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Xtandi caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Xtandi caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
4503.T·4503.T drug pipeline - Drug approvals (2 approvals on file for enzalutamide) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (enzalutamide) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.